mTOR信号通路与滑膜肉瘤研究进展

doi:10.11904/j.issn.1002-3070.2017.05.018

摘要/Abstract

摘要：

哺乳动物雷帕霉素靶蛋白(Mammalian target of rapamycin,mTOR)是一种丝/苏氨酸蛋白激酶,属于磷脂酰肌醇三激酶-相关激酶家族,通过影响Akt、4EBP1和S6K1等关键因子在肿瘤的发生发展中扮演重要角色。滑膜肉瘤(Synovial sarcoma,SS)是一种恶性程度极高的软组织肉瘤,早期外科手术及化疗是目前主流的治疗方式,但晚期生存率仍不理想,通过对信号通路转导的研究为滑膜肉瘤的治疗提供了新的研究方向。本文对近年来mTOR与滑膜肉瘤的相关研究进行综述。

关键词: mTOR, 滑膜肉瘤, 肿瘤

Abstract:

The mammalian target of rapamycin(mTOR)is a ser/threonine protein kinase,which belongs to the family of phosphatidylinositol trioxolase-related kinases.By influencing key factors such as AKT,4EBP1 and S6K1,play an important role in the development of tumors.Synovial sarcoma(SS)is a highly malignant soft tissue sarcoma,early surgery and chemotherapy is the mainstream of the current treatment.However,late survival rate is still not ideal.In order to provide A new direction for treatment of synovial sarcoma is provided through the reseach of signaling pathway conduction.In this paper,recent studies on mTOR and synovial sarcoma are reviewed.

Key words: mTOR, Synovial sarcoma, Tumor

中图分类号:

R736.1

刘乙澍综述, 曲国蕃审校. mTOR信号通路与滑膜肉瘤研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 477-480.

LIU Yishu, QU Guofan. Research progress of mTOR signaling pathway and synovial sarcoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 477-480.

参考文献

1 Weiss SW,Goldblum JR.Enzinger and weiss's soft tissue tumors[M].5th.St.Louis MO:Mosby Inc,2008:1161-1182.
2 Shi W,Indelicato DJ,Morris CG,et al.Long-term treatment outcomes for patients with synovial sarcoma:a 40-year experience at the University of Florida[J].Am J Clin Oncol,2013,36(1):83-88.
3 Haldar M,Randall RL,Capecchi MR.Synovial sarcoma:from genetics to genetic-based animal modeling[J].Clin Orthop Relat Res,2008,466(9):2156-2167.
4 Sudarsanam S,Johnson DE.Functional consequences of mTOR inhibition[J].Curr Opin Drug Discov Devel,2010,13(1):31-40.
5 Lempiäinen H,Halazonetis TD.Emerging common themes in regulation of PIKKs and PI3Ks[J].EMBO J,2009,28(20):3067-3073.
6 Heitman J,Movva NR,Hall MN.Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast[J].Science,1991,253(5022):905-909.
7 Sabatini DM,Erdjument-Bromage H,Lui M,et al.RAFT1:a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs[J].Cell,1994,78(1):35-43.
8 Laplante M,Sabatini DM.mTOR signaling in growth control and disease[J].Cell,2012,149(2):274-293.
9 Noda T,Ohsumi Y.Tor,a phosphatidylinositol kinase homologue,controls autophagy in yeast[J].J Biol Chem,1998,273(7):3963-3966.
10 Fingar DC,Salama S,Tsou C,et al.Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E[J].Genes Dev,2002,16(12):1472-1487.
11 Chen J,Zheng XF,Brown EJ,et al.Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue[J].Proc Natl Acad Sci U S A,1995,92(11):4947-4951.
12 Friedrichs N,Trautmann M,Endl E,et al.Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma[J].Int J Cancer,2011,129(7):1564-1575.
13 Cassinelli G,Zuco V,Gatti L,et al.Targeting the Akt kinase to modulate survival,invasiveness and drug resistance of cancer cells[J].Curr Med Chem,2013,20(15):1923-1945.
14 Choo AY,Yoon SO,Kim SG,et al.Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation[J].Proc Natl Acad Sci U S A,2008,105(45):17414-17419.
15 Skinner HD,Zheng JZ,Fang J,et al.Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha,HDM2,and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling[J].J Biol Chem,2004,279(44):45643-45651.
16 Guertin DA,Sabatini DM.Defining the role of mTOR in cancer[J].Cancer Cell,2007,12(1):9-22.
17 Huang J,Dibble CC,Matsuzaki M,et al.The TSC1-TSC2 complex is required for proper activation of mTOR complex 2[J].Mol Cell Biol,2008,28(12):4104-4115.
18 Brassesco MS,Cortez MA,Valera ET,et al.Cryptic syt/sxx1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive bcl2 overexpression[J].Cancer Genet Cytogenet,2010,196(2):189-193.
19 Peng C,Zhao H,Chen W,et al.Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma[J].Oncotarget,2016,7(41):66822-66834.
20 Setsu N,Kohashi K,Fushimi F,et al.Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma[J].Cancer,2013,119(19):3504-3513.
21 Palmerini E,Paioli A,Ferrari S.Emerging therapeutic targets for synovial sarcoma[J].Expert Rev Anticancer Ther,2014,14(7):791-806.
22 Morgan SS,Cranmer LD.Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells[J].BMC Res Notes,2014,7:812.
23 Demetri GD,Chawla SP,Ray-Coquard I,et al.Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy[J].J Clin Oncol,2013,31(19):2485-2492.
24 Phan AT,Dave B.The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors[J].Cancer Med,2016,5(10):2953-2964.
25 Yasui H,Naka N,Imura Y,et al.Tailored therapeutic strategies for synovial sarcoma:receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001[J].Cancer Lett,347(1):114-122.
26 Wagner LM,Fouladi M,Ahmed A,et al.Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma:a report from the Children's Oncology Group[J].Pediatr Blood Cancer,2015,62(3):440-444.
27Slotkin EK,Patwardhan PP,Vasudeva SD,et al.MLN0128,an ATP-competitive mTOR kinase inhibitor,with potent in vitro and in vivo antitumor activity as potential therapy for bone and soft-tissue sarcoma[J].Mol Cancer Ther,2015,14(2):395-406.
28 Cai Y,Xu P,Yang L,et al.HMGB1-mediated autophagy decreases sensitivity to oxymatrine in SW982 human synovial sarcoma cells[J].Sci Rep,2016,6:37845.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[4]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[5]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[6]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[7]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[8]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[9]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[10]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	阚钧, 周岱翰综述, 张恩欣审校. 肿瘤合并心血管疾病的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 558-561.
[14]	顾琦晟综述, 李继坤审校. 锰超氧化物歧化酶在肿瘤发生发展过程中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 562-566.
[15]	刘娟综述, 张澍田审校. 细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 575-578.